Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385471 | 0.83 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL12698321 | 0.81 | ALDH1A1 (0.35) | MAPK1 | |
| SCHEMBL4121606 | 0.77 | CYP1A2 (0.36) | CYP1A2HIF1A | |
| SCHEMBL11358276 | 0.65 | — | — | |
| SCHEMBL10967147 | 0.64 | MCL1 (0.56) | MAPK1CYP1A2 | |
| SCHEMBL3813382 | 0.63 | KDM4E (0.37) | MAPK1CYP1A2HIF1A | |
| SCHEMBL4128790 | 0.63 | CYP1A2 (0.36) | MAPK1CYP1A2HIF1A | |
| SCHEMBL22309984 | 0.62 | CYP1A2 (0.35) | MAPK1CYP1A2HIF1A | |
| SCHEMBL9547670 | 0.61 | MCL1 (0.48) | MAPK1CYP1A2 | |
| SCHEMBL3339309 | 0.61 | CYP1A2 (0.37) | MAPK1CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| EP-2668188-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | MAPK1 43/4885CYP1A2 558/4885HIF1A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.